Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Srilakshmi Bathini
Observed names:
S. Bathini,
Sri Bathini
Institutions:
University of Alabama at Birmingham,
O'Neal Comprehensive Cancer Center
Observed institutions:
University of Maryland, Baltimore,
University of Maryland Medical Center,
University of Alabama at Birmingham,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center,
O'Neal Comprehensive Cancer Center
ORCID:
0000-0001-8519-1333
Observed ORCID:
0000-0001-8519-1333
OpenAlex ID:
A5010236874
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab
2019
·
Srilakshmi Bathini
, Noa G. Holtzman
, et al.
·
American Journal of Hematology
·
39
PDF
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
2022
·
Sankalp Arora
, Carl Zainaldin
, et al.
·
Leukemia Research
·
21
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
2022
·
Carl Zainaldin
, Sankalp Arora
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
11
IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia
2022
·
Sydney Dunn-Valadez
, Srilakshmi Bathini
, et al.
·
Cancer Treatment and Research Communications
·
6
PDF
Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
2023
·
Pinkal Desai
, Jacqueline S. Garcia
, et al.
·
Blood
·
3
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen
2023
·
Sydney Dunn-Valadez
, Srilakshmi Bathini
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
2
Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
2022
·
Ofir Wolach
, Jacqueline S. Garcia
, et al.
·
Blood
·
2
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
2022
·
Carl Zainaldin
, Sankalp Arora
, et al.
·
Journal of Clinical Oncology
P519: Transfusion Independence Among Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax-based Combinations Vs Other Therapies: Results From the Aml Real World Evidence (arc) Initiative
2022
·
O. Wolach
, J. S. Garcia
, et al.
·
HemaSphere
CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia
2022
·
Sankalp Arora
, Carl Zainaldin
, et al.
·
Journal of the National Comprehensive Cancer Network
AML-430: Utility of End-of-Induction Bone Marrow Biopsy in APL Patients Treated with ATRA/ATO Regimen
2021
·
Sydney Dunn-Valadez
, Srilakshmi Bathini
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Poster: AML-430: Utility of End-of-Induction Bone Marrow Biopsy in APL Patients Treated with ATRA/ATO Regimen
2021
·
Sydney Dunn-Valadez
, Srilakshmi Bathini
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P1.06-14 Posterior Intercostal Lymph Node Positivity as a Prognostic Indicator of Overall Survival in Resectable Malignant Pleural Mesothelioma
2019
·
A. Hossain
, J. Chen
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
13
Citation count:
84
H-index:
4
I10-index:
3
Year
Topic
Type